Search
Align Summit 2026: Calluna Pharma has a S100A4 (a DAMP) targeting program currently in phase 2 for IPF that will read out in Q1 2027
CEO Mark Gaffney walks us through the idea of targeting a DAMP and, in this case, S100A4 specifically, and describes the differentiated profile Calluna hopes to see compared to currently marketed therapies for IPF. Coverage brought to you by
Oct 15
BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces. The lead asset will advance to two phase 2s next year
CEO Mark Gaffney describes the science behind the lead program, CAL101, which targets a Damage Associated Molecular Pattern protein...
Nov 5, 2024
.png){kind=logo}
